Brown Spider Venom Phospholipase-D Activity upon Different Lipid Substrates
Toxins · 2023
DOI: 10.3390/toxins15020109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2023. Verfasst von Daniele Chaves-Moreira und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, Federal University of Paraná (UFPR), Curitiba 81531-980, Brazil. Hauptthemen laut MEDLINE: Phospholipase D, Spider Venoms, Spiders. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Araucária-PR/SETI-PR/SESA-PR/MS-Decit/PPSUS, CAPES, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), FUNPAR-UFPR.
Abstract (Originalsprache)
Brown spider envenomation results in dermonecrosis, characterized by an intense inflammatory reaction. The principal toxins of brown spider venoms are phospholipase-D isoforms, which interact with different cellular membrane components, degrade phospholipids, and generate bioactive mediators leading to harmful effects. The Loxosceles intermedia phospholipase D, LiRecDT1, possesses a loop that modulates the accessibility to the active site and plays a crucial role in substrate. In vitro and in silico analyses were performed to determine aspects of this enzyme’s substrate preference. Sphingomyelin d18:1/6:0 was the preferred substrate of LiRecDT1 compared to other Sphingomyelins. Lysophosphatidylcholine 16:0/0:0 was preferred among other lysophosphatidylcholines, but much less than Sphingomyelin d18:1/6:0. In contrast, phosphatidylcholine d18:1/16:0 was not cleaved. Thus, the number of carbon atoms in the substrate plays a vital role in determining the optimal activity of this phospholipase-D. The presence of an amide group at C2 plays a key role in recognition and activity. In silico analyses indicated that a subsite containing the aromatic residues Y228 and W230 appears essential for choline recognition by cation-π interactions. These findings may help to explain why different cells, with different phospholipid fatty acid compositions exhibit distinct susceptibilities to brown spider venoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology, Federal University of Paraná (UFPR), Curitiba 81531-980, Brazil.
- Department of Physics, Multi-User Center for Biomolecular Innovation, State University of São Paulo (UNESP), São Paulo 05315-970, Brazil.
- Department of Structural and Molecular Biology, State University of Ponta Grossa (UEPG), Ponta Grossa 84030-900, Brazil.
- Department of Pharmacology, University of California San Diego, La Jolla, CA 92093, USA.
ORCID-Profile: Daniele Chaves-Moreira, Fábio Rogério de Moraes, Jorge Enrique Hernández González, Olga Meiri Chaim, Andrea Senff-Ribeiro, Raghuvir Krishnaswamy Arni
Förderung
- Fundação Araucária-PR/SETI-PR/SESA-PR/MS-Decit/PPSUS
- CAPES, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- FUNPAR-UFPR
- Sao Paulo Research Foundation
Zitieren
APA
Chaves-Moreira, D., Gremski, L. H., de Moraes, F. R., Vuitika, L., Wille, A. C. M., Hernández González, J. E., Chaim, O. M., Senff-Ribeiro, A., Arni, R. K., & Veiga, S. S. (2023). Brown Spider Venom Phospholipase-D Activity upon Different Lipid Substrates. Toxins. https://doi.org/10.3390/toxins15020109
Vancouver
Chaves-Moreira D, Gremski LH, de Moraes FR, Vuitika L, Wille ACM, Hernández González JE, et al. Brown Spider Venom Phospholipase-D Activity upon Different Lipid Substrates. Toxins. 2023. doi:10.3390/toxins15020109
BibTeX
@article{ChavesMoreira2023,
author = {Chaves-Moreira, Daniele and Gremski, Luiza Helena and de Moraes, Fábio Rogério and Vuitika, Larissa and Wille, Ana Carolina Martins and Hernández González, Jorge Enrique and Chaim, Olga Meiri and Senff-Ribeiro, Andrea and Arni, Raghuvir Krishnaswamy and Veiga, Silvio Sanches},
title = {Brown Spider Venom Phospholipase-D Activity upon Different Lipid Substrates},
journal = {Toxins},
year = {2023},
doi = {10.3390/toxins15020109}
}
EUVIMED